Achieve Life Sciences Inc Cash Flow Conversion Efficiency
Achieve Life Sciences Inc cash flow conversion efficiency. Based on the latest financial reports, Achieve Life Sciences Inc (SP4P) has a cash flow conversion efficiency ratio of -0.649x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.93 Million ≈ $-8.10 Million USD) by net assets (€10.68 Million ≈ $12.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Achieve Life Sciences Inc (2016–2025)
Cash flow conversion efficiency of Achieve Life Sciences Inc from 2016 to 2025. This chart illustrates how Achieve Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Achieve Life Sciences Inc for real-time trading data and today's change.
Achieve Life Sciences Inc Cash Flow Conversion Ratio Explained
Achieve Life Sciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Achieve Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Achieve Life Sciences Inc ranked by their cash flow conversion efficiency. Also see market cap of Achieve Life Sciences Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sparebank 1 Ostfold Akershus
OL:SOAG
|
0.060x |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
0.018x |
|
BES Engineering Co
TW:2515
|
-0.007x |
|
Guangxi Nanning Waterworks Co
SHG:601368
|
0.039x |
|
SeaBird Exploration Plc
OL:SBX
|
0.148x |
|
Konka Group Co Ltd
SHE:000016
|
0.068x |
|
Shen Zhen Bauing Construction Holding Group Co Ltd
SHE:002047
|
2.259x |
|
Meridian Mining UK Societas
TO:MNO
|
-0.036x |
Annual Cash Flow Conversion Efficiency for Achieve Life Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Achieve Life Sciences Inc from 2016 to 2025. Review how financially flexible is Achieve Life Sciences Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €21.52 Million ≈ $25.16 Million |
€-49.47 Million ≈ $-57.83 Million |
-2.299x | -61.38% |
| 2024-12-31 | €20.90 Million ≈ $24.43 Million |
€-29.77 Million ≈ $-34.80 Million |
-1.424x | -108.43% |
| 2023-12-31 | €-1.45 Million ≈ $-1.69 Million |
€-24.48 Million ≈ $-28.62 Million |
16.905x | +473.82% |
| 2022-12-31 | €8.30 Million ≈ $9.71 Million |
€-37.55 Million ≈ $-43.90 Million |
-4.522x | -330.76% |
| 2021-12-31 | €28.04 Million ≈ $32.78 Million |
€-29.44 Million ≈ $-34.42 Million |
-1.050x | -190.52% |
| 2020-12-31 | €37.29 Million ≈ $43.59 Million |
€-13.47 Million ≈ $-15.75 Million |
-0.361x | +57.13% |
| 2019-12-31 | €18.05 Million ≈ $21.10 Million |
€-15.22 Million ≈ $-17.79 Million |
-0.843x | -25.40% |
| 2018-12-31 | €15.80 Million ≈ $18.47 Million |
€-10.62 Million ≈ $-12.42 Million |
-0.672x | +41.84% |
| 2017-12-31 | €7.88 Million ≈ $9.21 Million |
€-9.11 Million ≈ $-10.65 Million |
-1.156x | -10752.47% |
| 2016-12-31 | €18.97 Million ≈ $22.17 Million |
€-202.00K ≈ $-236.16K |
-0.011x | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more